Peyronie Disease Clinical Trial
Official title:
Addition of Pelvic CT With Agatston Calcium Score for Patients With Peyronie Disease May Change Management Decisions in Patients With Calcified Plaque
The purpose of this study is to find out how including a CT exam of the penis can help urologists make treatment decisions for patients with calcified Peyronie's disease.
Peyronie disease (PD) affects up to 10% of men with fibrosing penile plaques causing penile pain and progressing to deformity. Calcified plaque develops in up to 20% of these patients, excluding them from medical therapy with collagenase injection and often requiring more extensive surgery for treatment. PDDU identifies plaque distribution and characteristics while the Doppler exam evaluates for any underlying erectile dysfunction. Calcification can make PDDU difficult to identify the full extent of plaque since the shadow caused by calcification may prevent accurate measurement and over or underestimate the plaque size. In addition, the ultrasound exam is operator dependent and requires injection of an agent to induce erection. Since current clinical practice excludes men with any degree of calcification presumed on physical examination or demonstrated on PDDU from receiving injection therapy they may be triaged to surgical management instead. A prior study found the presence of calcifications at ultrasound had odd ratio 1.75 of patient progressing to surgical management, while fibrosis without calcification did not have increased odds of surgical management. Noncontrast pelvis CT provides three dimensional detail of calcified plaque including parts of the penis that are difficult to image with PDDU, and calcification does not have artifact on CT. By adding non-contrast pelvis CT with Agatston calcium scoring to PDDU and clinical parameters of penile deformity, patients may be better stratified into the appropriate treatment pathway. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03774264 -
Treatment Response to Xiaflex for Men With Peyronie's Disease
|
||
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Active, not recruiting |
NCT05871177 -
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)
|
N/A | |
Recruiting |
NCT05768867 -
French Translation and Validation of the PEYronie's Disease QUESTionnaire
|
||
Recruiting |
NCT04512287 -
PRP for Treatment of Peyronie's Disease
|
Phase 2 | |
Withdrawn |
NCT05646602 -
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
|
N/A | |
Recruiting |
NCT03530540 -
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
|
N/A | |
Completed |
NCT04052217 -
Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse
|
N/A | |
Recruiting |
NCT06303661 -
Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease
|
N/A | |
Recruiting |
NCT06065436 -
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
|
N/A | |
Recruiting |
NCT05316714 -
Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment
|
N/A | |
Completed |
NCT04370652 -
Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum
|
||
Recruiting |
NCT04821115 -
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
|
N/A |